Loading...
•
Sep 30, 2021
Sangamo Q3 2021 Earnings Report
Reported third quarter financial results and provided business and clinical highlights.
Key Takeaways
Sangamo Therapeutics reported a net loss of $47.7 million, or $0.33 per share, for the third quarter ended September 30, 2021. Revenues for the quarter were $28.6 million. The company is advancing its gene therapy portfolio and has initiated planning for a Phase 3 Fabry disease clinical trial.
First four Fabry disease patients dosed exhibited above normal α-Gal A activity; Phase 3 planning initiated.
Preliminary proof-of-concept data for sickle cell disease program will be presented at ASH as clinical program advances.
Four hemophilia A patients at highest dose experienced mean FVIII activity of 30.9% at week 104.
First renal transplant patient enrolled, expect two patients to be dosed by mid-2022.
Forward Guidance
Sangamo is revising its full-year operating expense guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...